Rosuvastatin and cardio vascular events in patients undergoing hemodialysis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F09%3A00208822" target="_blank" >RIV/00216208:11150/09:00208822 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/09:8698 RIV/00064165:_____/09:8698

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Rosuvastatin and cardio vascular events in patients undergoing hemodialysis

Original language description

In this international, multicenter, randomized, double-blind, prospective trial involving 2776 maintenance haemodialysis patients, authors randomly assigned patients to receive rosuvastatin, 10 mg daily, or placebo. Median follow-up period was 3.8 years.The initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FE - Other fields of internal medicine

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2009

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

—

Volume of the periodical

360

Issue of the periodical within the volume

14

Country of publishing house

US - UNITED STATES

Number of pages

13

Pages from-to

—

UT code for WoS article

000264751800005

EID of the result in the Scopus database

—